Citius Pharma raises ~$15M in registered direct offering of common stock and warrants

Citius Pharmaceuticals, Inc.

Sold 21.43M shares and warrants to buy 21.43M shares at $0.70/combined unit.
Warrants exercisable at $0.75/share from 6 months after issuance, expire in 5 years.
Gross proceeds ~$15M; net proceeds ~$13.8M after placement agent fees and expenses.
Proceeds for general corporate purposes, including pre-clinical/clinical development and working capital.
Offering closed April 30, 2024; H.C. Wainwright acted as exclusive placement agent.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Citius Pharmaceuticals, Inc. entered into Purchase Agreement with certain institutional investors (effective 2024-04-25).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Effective: 2024-04-25

Exact text from the filing

On April 25, 2024, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 21,428,574 shares of the Company’s common stock, par value $0.001 per share (the “Shares”) and warrants (the “Warrants”) to purchase up to 21,428,574 shares of common stock.

View on SEC.gov

284 material agreements filed in the last 30 days. Browse all material agreements →

Citius Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-037861

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.